Search Results - "Harrer, Grant W."

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032

    Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032 by Smith, David C, Tangen, Cathy M, Van Veldhuizen, Peter J, Harrer, Grant W, Golshayan, Ali, Mills, Glenn M, Vogelzang, Nicholas J, Thompson, Ian M, Hussain, Maha H.A

    Published in Urology (Ridgewood, N.J.) (01-05-2011)
    “…Objectives To assess the efficacy of a multiagent taxane-based chemotherapy combined with hormonal therapy in men with metastatic androgen-dependent prostate…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate: Southwest Oncology Group (SWOG) S0032

    Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate: Southwest Oncology Group (SWOG) S0032 by Smith, David C., Tangen, Cathy M., Hussain, Maha H.A., Van Veldhuizen, Peter J., Harrer, Grant W., Stuart, Robert K., Mills, Glenn M., Vogelzang, Nicholas J., Thompson, Ian M.

    Published in Urology (Ridgewood, N.J.) (21-02-2011)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: